

I certify that on 2/25/02, which is the date I am signing this certificate, this correspondence and all identified attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Trudi Thompson
Trudi Thompson

PATENT

Applicant: Manning et al.

Serial No.: 09/665493

Filed: September 20, 2000

Title: USE OF RECOMBINANT GENE
DELIVERY VECTORS FOR
TREATING OR PREVENTING
DISEASES OF THE EYE

Examiner: T. Ton

Group Art Unit: 1632

Atty Docket No.: 20263.40

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

OK to enter
TNT

In response to the restriction requirement in the Office Action dated December 19, 2001, applicant provisionally elects claims 17-22 and 26-29 drawn to a method of inhibiting neovascular disease of the eye, by administering intraocularly a gene therapy vector that directs the expression of an anti-angiogenic factor, classified in class 514, subclass 44, for example, and antiangiogenic factors: soluble Flt-1 for examination.

Applicant makes this election with traverse.

Respectfully submitted,



February 25, 2002

Louis C. Cullman
Registration No. 39,645OPPENHEIMER WOLFF & DONNELLY LLP
840 Newport Center Drive, Suite 700
Newport Beach, CA 92660
Telephone: 949.823.6000
Facsimile: 949.823.6100

PATENT
20263-40/US
LCCClient Name: Chiron Corporation
Applicant: Manning, Jr., et al.,
Serial No.: 09/665,493

Filed: 9-20-00

Title: Use of Recombinant Gene Delivery Vectors for Treating or Preventing Diseases of
the EyePATENT
20263-40


Please acknowledge receipt of:

1. Petition for Extension of Time (1 pg)(original +1)
2. Response to Restriction Requirement (1 pg)

Diseases of

The U.S. Patent and Trademark Office Mail Room stamp hereon acknowledges receipt of
the items indicated above on the date shown.

Mailed: February 25, 2002



Receipt of

-1